Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Recent Posts
- Adolore BioTherapeutics Announces FDA Orphan Drug Designation for its Kv7-activating rdHSV-CA8* Therapy in the Treatment of Erythromelalgia
- Dr. Roy Levitt, Executive Chairman of Adolore BioTherapeutics, Presented at the Next Generation Gene Therapy Vectors Summit
- Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice
- Adolore BioTherapeutics to Present at Festival of Biologics USA 2025
- Adolore BioTherapeutics to Present CA8* Neuromodulating Gene Therapy at the 2025 NANS Annual Meeting
Recent Comments
No comments to show.
